P038 Notch pathway in fibrosis: a new anti-fibrotic therapy in Crohn's disease?

نویسندگان

چکیده

Abstract Background Fibrosis represent the main complications related to Crohn's disease (CD). Notch signalling mediate fibrogenic process, including epithelial-mesenchymal transition (EMT) and fibroblast senescence but its role in CD fibrosis is currently unknown. Previous studies have shown a high expression of NOTCH4, NOTCH3, DLL3 DLL4 fibrotic tissue. mainly activates transcription factors involved EMT, macrophages could act as possible source (Edo, et al., 2022. JCC (i200)).The general aim present study determine potential pathway therapeutic target intestinal associated with CD. Specifically, we pretend: analyze localization NOTCH3/4 receptors tissue patients complicated; relevance EMT; fibroblast. Methods We analyzed samples from complicated lesions: by IH protein markers (BCL2 P53) WB. carry out vitro analyze: HES1 (effector pathway) EMT DLL4-HT29 treated cells transfected miNOTCH3 or miNOTCH4; proteins HSIF fibroblasts DLL3. Results NOTCH3 was located preferentially muscular areas -muscularis mucosa, endothelium muscularis externa- striking staining infiltrated mucosa unaffected area. NOTCH4 found more specifically crypts well lamina propria mucosa. The showed elevated levels BCL2 P53, compared same patient. increased HT29 cells, silencing significantly reverted these markers. produced no significant changes after treatment. DLL3, not DLL4, increase BCL2, vehicle (Figure). Conclusion NOTCH regulation key cellular functions processes essential for pathogenesis patients. DLL4-NOTCH4 interaction triggers mesenchymal epithelial colonic while seems relevant activation fibroblasts.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Diet-Therapy in Pediatric Crohn’s Disease: A New Approach

 nflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), has become one of the most common chronic conditions all over the world. The prevalence of IBD is growing rapidlyin developing countries along with nutrition transition. IBD affects children as well as adults, with 15-20% of patients being diagnosed during childhood. The onset of disea...

متن کامل

Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis

BACKGROUND Progressive fibrous thickening of the peritoneal membrane is a complication of long-term peritoneal dialysis (PD). TGF-β/Smad pathway activation, inflammation, and neoangiogenesis play important roles in peritoneal membrane (PM) changes induced by PD. Recently, histone deacetilase inhibitors (HDACi) have shown anti-fibrotic and anti-inflammatory effects in different experimental mode...

متن کامل

HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease

In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein kinase 2 (HIPK2), a novel regulator of fibrosis that acts upstream of major fibrosis signaling pa...

متن کامل

Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis

RATIONALE Pulmonary fibrosis is a progressive disease with only few treatment options available at the moment. Recently, the nucleoside uridine has been shown to exert anti-inflammatory effects in different animal models, e.g. in acute lung injury or bronchial asthma. METHOD Therefore, we investigated the influence of uridine supplementation on inflammation and fibrosis in the classical bleom...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Crohn's and Colitis

سال: 2023

ISSN: ['1876-4479', '1873-9946']

DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0168